Table 4.
Plaque phenotypic characteristics after anti-CD25 treatment
| Cd40l+/+ Apoe−/− | Cd40l+/+Apoe−/− + anti-CD25 | Cd40l−/− Apoe−/− | Cd40l+/+Apoe−/− + anti-CD25 | |
|---|---|---|---|---|
| % CD3 | 4.5 ± 0.8 | 4.9 ± 0.4 | 2.7 ± 0.7* | 2.9 ± 0.4 |
| % CD45 | 9.7 ± 1.7 | 8.3 ± 1.7 | 6.8 ± 1.2 | 7.4 ± 1.6 |
| % Mac3 | 56.4 ± 8.2 | 60.6 ± 4.9 | 64.2 ± 4.8 | 58.7 ± 3.2 |
| MAC-3 Abs | 144.2 ± 23.2 | 161.4 ± 19.6 | 151.6 ± 13.6 | 163.7 ± 27.2 |
| Caspase-3+ | 2.0 ± 0.4 | 1.7 ± 0.3 | 2.0 ± 0.2 | 2.0 ± 0.2 |
| % α-SMA | 24.7 ± 5.7 | 14.5 ± 2.2 | 24.6 ± 4.6 | 16.1 ± 2.7 |
| % SR | 64.2 ± 5.7 | 57.1 ± 2.2 | 55.1 ± 2.2 | 66.6 ± 3.6 |
| % LC | 17.4 ± 3.5 | 18.7 ± 2.4 | 12.9 ± 3.1 | 18.1 ± 3.7 |
*
P < .05 vs Cd40l+/+Apoe−/−.